Myomo Inc

Myomo Inc

MYO · AMEX · Healthcare / Medical Devices

1.23USD+0.02 (+1.65%)

Price History

Full chart

Market Stats

Previous Close1.21
Open1.24
Day Range1.20 – 1.27
52-Week Range0.605 – 1.89
Volume390.88K
Market Cap63.77M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.35
Dividend Yield0.00%
Beta1.50
50-Day Avg1.34
200-Day Avg1.03

About

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device; MyoGames, a virtual training platform; and MyoPro 2x Video Library. In addition, the company offers MyoCare, a post-delivery program that provides follow-up care with clients, therapists, and referral sources; MYOMO; MyoPal; and MyoCoach. Its products are designed to help adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, veteran's administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Paul R. Gudonis
  • Employees194
  • Headquarters45 Blue Sky Dr., Burlington, MA, United States, 01803, USA
  • Websitehttps://myomo.com

Leadership

  • Mr. Paul R. GudonisPresident, CEO & Chairman · b. 1955
  • Mr. David A. HenryChief Financial Officer · b. 1961
  • Dr. Harry Kovelman M.D.Chief Medical Officer · b. 1959
  • Mr. Colin AndersonGlobal Director of Operations
  • Ms. Galina ShtivelmanSenior Director of Human Resources
  • Mr. Micah J. MitchellChief Commercial Officer · b. 1976
  • Ms. Kathy SawyersSr. Director of Clinical Outcomes
  • Mr. Malcolm G. BockVice President of Engineering & Product Strategy

Financials

Income Statement

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue913.25K689.67K1.10M1.56M2.44M3.84M7.58M13.86M15.56M19.24M32.55M40.93M
Growth (%)--24.48%+59.97%+41.29%+56.79%+57.02%+97.60%+82.72%+12.26%+23.70%+69.17%+25.73%
Cost of Revenue211.58K244.41K282.16K505.28K728.28K917.62K2.60M3.54M5.30M6.06M9.37M14.04M
Gross Profit701.67K445.26K821.11K1.05M1.72M2.92M4.98M10.31M10.25M13.18M23.19M26.89M
Gross Margin76.83%64.56%74.42%67.59%70.20%76.09%65.71%74.42%65.91%68.51%71.23%65.70%
Operating Expense3.44M3.98M4.10M7.60M12.24M13.72M15.49M20.58M20.93M21.41M29.39M41.29M
Operating Income-2.74M-3.53M-3.28M-6.55M-10.53M-10.80M-10.50M-10.27M-10.67M-8.23M-6.21M-14.40M
Operating Margin-300.17%-512.35%-296.84%-420.06%-430.77%-281.29%-138.50%-74.10%-68.61%-42.78%-19.07%-35.19%
EBITDA-2.74M-3.53M-3.27M-6.54M-10.46M-10.70M-10.98M-9.95M-10.11M-7.47M-5.04M-12.38M
EBITDA Margin-299.50%-511.58%-296.14%-419.32%-427.92%-278.81%-144.80%-71.79%-64.98%-38.84%-15.49%-30.24%
Net Income-3.53M-4.48M-3.62M-12.10M-10.32M-10.71M-11.56M-10.37M-10.72M-8.15M-6.18M-15.57M
Net Income Margin-386.29%-649.90%-327.84%-776.04%-422.11%-279.15%-152.49%-74.86%-68.92%-42.34%-19.00%-38.05%
R&D675.21K869.13K1.12M1.75M1.84M2.16M1.67M2.56M2.48M2.64M4.77M6.94M
R&D as % of Total Revenue73.93%126.02%101.60%112.37%75.23%56.30%22.01%18.46%15.96%13.70%14.66%16.97%
Interest Expense00342.02K358.92K358.92K113.63K474.71K15.34K88.73K--927.80K
Interest Expense % of Total Revenue0.00%0.00%31.00%23.02%14.68%2.96%6.26%0.11%0.57%--2.27%

Balance Sheet

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets3.05M1.51M1.66M13.97M8.28M6.60M14.71M20.10M10.16M14.58M42.24M38.64M
Total Liabilities2.33M2.85M19.19M1.53M1.86M4.77M3.14M4.69M3.80M5.59M17.53M27.23M
Total Equity712.11K-1.34M-17.53M12.45M6.43M1.82M11.57M15.41M6.36M8.99M24.71M11.40M
Cash2.42M1.04M797.17K12.96M6.54M4.47M12.24M15.52M5.35M6.87M24.37M14.13M
Total Debt1.39M2.05M5.45M--2.65M173.44K735.00K553.91K601.30K8.11M19.38M
Net Debt-1.03M1.01M4.66M-12.96M-6.54M-1.81M-12.07M-14.79M-4.79M-6.27M-16.27M5.25M

Cash Flow

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.55M-3.33M-3.20M-6.15M-9.61M-10.34M-9.03M-9.55M-10.23M-6.17M-3.29M-14.51M
Investing Cash Flow-3.53K-27.94K-1.86K-67.00K-126.87K-51.99K-45.75K-326.46K-310.79K-2.03M259.98K-7.06M
Financing Cash Flow3.44M1.98M2.96M18.38M3.34M8.32M16.78M13.17M376.86K9.71M20.93M11.43M
Capital Expenditure3.53K27.94K1.86K67.00K126.87K51.99K45.75K326.46K111.79K145.82K1.36M1.74M
Free Cash Flow-2.55M-3.36M-3.20M-6.22M-9.73M-10.39M-9.08M-9.87M-10.35M-6.32M-4.65M-16.25M
Dividends Paid---0-2.71M1.85K-----
FCF to OCF100.14%100.84%100.06%101.09%101.32%100.50%100.51%103.42%101.09%102.36%141.34%112.01%
Dividend Paid to FCF---0.00%--26.05%-0.02%-----

Earnings

Report DateAug 14, 2017Nov 6, 2017Mar 7, 2018May 9, 2018Aug 7, 2018Nov 5, 2018Mar 7, 2019May 13, 2019Aug 8, 2019Nov 12, 2019Mar 12, 2020May 14, 2020Aug 10, 2020Nov 10, 2020Mar 10, 2021May 5, 2021Aug 9, 2021Nov 10, 2021Mar 9, 2022May 11, 2022Aug 3, 2022Nov 10, 2022Mar 13, 2023May 10, 2023Aug 9, 2023Nov 7, 2023Mar 7, 2024May 8, 2024Aug 6, 2024Nov 6, 2024Mar 5, 2025May 7, 2025Aug 11, 2025Nov 10, 2025Mar 16, 2026May 7, 2026Aug 5, 2026Nov 9, 2026
EPS Estimate--9.00-9.90-5.70-5.40-6.90-7.50-6.00-5.10-4.95-4.59-2.32-1.34-1.05-0.49-0.68-0.61-0.46-0.49-0.53-0.43-0.43-0.42-0.13-0.03-0.09-0.06-0.09-0.07-0.04-0.02-0.08-0.11-0.11-0.08-0.11-0.10-0.08
EPS Actual-0.24-6.30-7.20-5.95-6.36-6.43-6.51-5.10-4.50-4.80-4.61-2.47-1.02-0.66-0.37-0.57-0.46-0.36-0.52-0.41-0.42-0.40-0.29-0.11-0.04-0.06-0.07-0.10-0.03-0.03-0.01-0.08-0.11-0.09-0.09-0.09-0.07-
Surprise-30.00%27.27%-4.39%-17.78%6.81%13.20%15.00%11.76%3.03%-0.44%-6.47%23.88%37.14%24.49%16.18%24.59%21.74%-6.12%22.64%2.33%6.98%30.95%15.38%-33.33%33.33%-16.67%-11.11%57.14%25.00%57.08%0.00%0.00%18.18%-1.43%18.18%30.00%-
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap63.77M
Enterprise Value71.59M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales1.47
Price / Book11.14
EPS-0.35
Book Value0.147
Revenue (TTM)43.26M
Gross Profit (TTM)29.57M
EBITDA-10.52M
Profit Margin-33.53%
Operating Margin-19.26%
Return on Equity-123.76%
Return on Assets-19.76%
Shares Outstanding39.61M
Shares Float27.87M
Beta1.50
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 5 analystsTarget 4.64
  • Strong Buy
    3
  • Buy
    2